Discontinuation of Beta-Blocker Therapy after Myocardial Infarction
Karam Choi·Joo-Yong Hahn·Weon Kim·J H Doh·Juhan Kim·Y H Park·Sung Gyun Ahn·Sang Min Kim·Byung Ryul Cho·Chang-Wook Nam·Jang Hyun Cho·Seung‐Jae Joo·Jon Suh·Jin-Ok Jeong·Woo Jin Jang·Choong Won Goh·Chang-Hwan Yoon·Jin-Yong Hwang·Jong Pil Park·Sang Rok Lee·Eun–Seok Shin·Byung‐Soo Kim·Cheol Woong Yu·Sung-Ho Her·H K Kim·Kyu Tae Park·Juwon Kim·Jihoon Kim·Taek Kyu Park·Joo Myung Lee·Juhee Cho·J Yang·Young Bin Song·Su‐Yeon Choi·Hyeon-Cheol Gwon·Eliseo Güallar·Seong-Hoon Lim·Danbee Kang
Among patients who received beta-blocker therapy beyond the first year after a myocardial infarction, discontinuation of beta-blocker therapy was noninferior to continuation with respect to a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure. (Funded by Patient-Centered Clinical Research Coordinating Center in the Ministry of Health and Welfare, South Korea; SMART-DECISION ClinicalTrials.gov number, NCT04769362.).